Notice of Annual General Meeting/Proxy Form
Released
Released
Announcement PDF
ORBITAL CORPORATION LIMITED
ABN 32 009 344 058
Notice of 2023 Annual General Meeting
10:00am (AWST), Thursday, 16 November 2023
Orbital Office
4 Whipple Street
Balcatta, Western Australia
1
Orbital Corporation Limited
NOTICE OF 2023 ANNUAL GENERAL MEETING
The 2023 Annual General Meeting of Orbital Corporation Limited ACN 009 344 058 (Orbital or the
Company) will be held at 10.00am (AWST) on Thursday, 16 November 2023 at the Orbital Offices,
4 Whipple Street, Balcatta, Western Australia 6021.
Dear Shareholder
It is my pleasure to invite you to attend Orbital’s Annual General Meeting
(AGM) to be held at 10.00am Australian Western Standard Time
(AWST) on Thursday, 16 November 2023 at the Orbital Offices, 4
Whipple Street, Balcatta, Western Australia 6021 (Meeting).
Voting on the resolutions at the Meeting is important and if you are not
able to attend I encourage you to exercise your voting rights by
completing and returning the enclosed Proxy Form. If you nominate a
proxy, please carefully consider the related comments in this Notice.
As a Shareholder your participation at the Meeting is important. The
Meeting is an ideal opportunity to engage directly with Orbital’s Board
and senior management team and I encourage you to attend.
Completed Proxy Forms must be returned to and received by the
Company’s Share Registry, Link Market Services Limited, by 10:00am
(AWST) on Tuesday, 14 November 2023, either by posting the enclosed
form or lodging it online at www.linkmarketservices.com.au.
Highlights announced by Orbital since the Company’s last annual
general meeting include a signed MoU with a UK customer,
achievement of performance milestones totalling $4.5m in grant funding
against government loans, engine development milestones with key
customers and new customer contracts.
An electronic copy of the Company’s 2023 Annual Report is available to
download or view on Orbital’s website at: https://orbitaluav.com/. Hard
copies have been sent to those Shareholders who previously elected to
receive the report in this format.
This Notice of Meeting details the items of business to be conducted at
the AGM. Your Directors believe that each of the resolutions is in the
best interests of the Company and its Shareholders.
On behalf of the Board and management team I look forward to your
company at the Meeting.
Yours faithfully
John Welborn
Chairman
13 October 2023
2
Orbital Corporation Limited
NOTICE OF 2023 ANNUAL GENERAL MEETING
Shareholder
Approval
Items of Business
Voting
Restrictions
and Further
Details
ORDINARY BUSINESS
1.
CHAIRMAN’S ADDRESS AND
THE CEO’S REPORT
The Chairman and the CEO will make presentations on
the performance of the Company during the financial
year ended 30 June 2023, as well as other strategic
and operational activities of the Company.
Not applicable
5
2.
DISCUSSION OF FINANCIAL
STATEMENTS AND REPORTS
To receive and consider the Financial Report,
Directors’ Report and Auditor’s Report for the year
ended 30 June 2023.
Not applicable
5
3.
REMUNERATION REPORT
To adopt the Remuneration Report for the year ended
30 June 2023.
Non-binding
5
4.
RE-ELECTION OF DIRECTOR –
MR KYLE ABBOTT
That, for the purposes of Listing Rule 14.4, article 9.3
of the Company’s constitution and for all other
purposes, Mr Frederick Kyle Abbott be re-elected as a
Director.
Ordinary
resolution
5
SPECIAL BUSINESS
5.
RATIFICATION OF TRANCHE 1
PLACEMENT SHARES ISSUED
UNDER LISTING RULE 7.1
That, pursuant to and in accordance with Listing Rule
7.4 and for all other purposes, Shareholders ratify and
approve the prior issue by the Company under Listing
Rule 7.1 of 17,318,531 Shares (at an issue price of
$0.14 per Share) pursuant to the Tranche 1 Placement,
as detailed in the Explanatory Notes.
Ordinary
resolution
6
6.
RATIFICATION OF TRANCHE 1
PLACEMENT SHARES ISSUED
UNDER LISTING RULE 7.1A
That, pursuant to and in accordance with Listing Rule
7.4 and for all other purposes, Shareholders ratify and
approve the prior issue by the Company under Listing
Rule 7.1A of 4,110,041 Shares (at an issue price of
$0.14 per Share) pursuant to the Tranche 1 Placement,
as detailed in the Explanatory Notes.
Ordinary
resolution
6
7.
ISSUE OF TRANCHE 2
PLACEMENT SHARES TO UIL
LIMITED
That, pursuant to and in accordance with Listing Rule
10.11 and for all other purposes, Shareholders
authorise and approve the issue of up to 7,142,857
Shares (at an issue price of $0.14 per Share) to UIL
Limited pursuant to the Tranche 2 Placement, on the
terms and conditions in the Explanatory Notes.
Ordinary
resolution
7
8.
ADDITIONAL CAPACITY TO
ISSUE EQUITY SECURITIES
That, pursuant to and in accordance with Listing Rule
7.1A and for all other purposes, Shareholders
authorise and approve the issue of equity securities (as
defined in the Listing Rules, Equity Securities) of up
to 10% of the issued capital of the Company (at the
time of the issue) calculated in accordance with the
formula prescribed in Listing Rule 7.1A.2 and on the
terms and conditions in the Explanatory Notes.
Special
resolution
8
3
Orbital Corporation Limited
NOTICE OF 2023 ANNUAL GENERAL MEETING
VOTING
Voting Entitlement
The Company’s shareholders (Shareholders) recorded on the Company’s
register of members at 4:00pm (AWST) on Tuesday, 14 November 2023
(Voting Entitlement Date) will be entitled to vote on Items at the Company’s
2023 annual general meeting (Meeting).
Becoming a Shareholder
Persons who become registered Shareholders between the date of this
notice of meeting (Notice) and the Voting Entitlement Date, and wish to vote
at the Meeting by proxy should call +61 1300 554 474 and request an
additional personalised voting form.
Persons who become beneficial Shareholders between the date of this
Notice and the Voting Entitlement Date, and wish to vote at the Meeting by
proxy should contact their broker or intermediary for instructions on how to
do so.
Voting Procedure
Under the Company’s constitution (Constitution), each poll will be
conducted as directed by the chair of the Meeting (the Chair).
Shareholders can vote in one of two ways:
•
by attending the Meeting and voting; or
•
by appointing a proxy to attend and vote on their behalf.
Shareholders are asked to arrive at the venue 15 minutes prior to the time
designated for the Meeting, if possible, so that the Company may check their
Shareholding against the Company’s share register and note attendances.
Voting Restrictions
The voting prohibitions under the Corporations Act 2001 (Cth) (Corporations
Act) and voting exclusions under the ASX Listing Rules (Listing Rules) for
each Item are set out in the Explanatory Notes to this Notice.
PROXY FORMS
Proxy Form
Enclosed with this Notice is a personalised proxy form (Proxy Form). The
Proxy Form allows Shareholders who are not attending the Meeting to
appoint a proxy to vote on their behalf.
If you hold fully paid ordinary shares in the capital of the Company (Shares)
in more than one capacity, please complete the Proxy Form that is relevant
to each holding.
Appointing proxies
Shareholders, who are entitled to attend and vote at the Meeting, may
appoint a proxy to act generally at the Meeting and to vote on their behalf.
A proxy need not be a Shareholder of the Company.
A Shareholder entitled to attend and vote can appoint up to two proxies, and
should specify the proportion or number of votes each proxy is appointed and
authorised to exercise. If no proportion or number is specified, each proxy
may exercise half of the Shareholder’s votes. If you wish to appoint two
proxies please call +61 1300 554 474 and request an additional Proxy Form.
A corporate Shareholder or proxy must appoint a person as its corporate
representative.
Undirected proxies
Any proxy given to:
•
a member of the Company’s key management personnel (those
persons having authority and responsibility for planning, directing and
controlling the activities of the Company and its consolidated group,
directly or indirectly, including any director (whether executive or
otherwise) of the Company (Directors) or of an entity within the
consolidated group) (Key Management Personnel), other than the
Chair; or
•
their closely related parties (including a spouse, child, dependent or
other close family members, as well as any companies they control)
(Closely Related Parties),
for Item 3 will not be counted unless Shareholders specify how the proxy is
to vote.
Any undirected proxy given to the Chair for Item 3 by a Shareholder entitled
to vote on Item 3 will be voted by the Chair in favour of the Item, in
accordance with the express authorisation on the Proxy Form (even though
Item 3 is connected directly or indirectly with the remuneration of members
of Key Management Personnel). The Chair intends to vote all valid undirected
proxies for all Items in favour of those Items.
Power of attorney and corporate representatives
If the Proxy Form is signed by an attorney, the power of attorney or a certified
copy of it must be sent with the Proxy Form.
A body corporate member may elect to appoint a representative, rather than
appoint a proxy. Where a body corporate appoints a representative, written
proof of the representative’s appointment must be to be lodged with, or
presented to, the Company before the Meeting.
A body corporate appointed as a proxy must also lodge a certificate of
appointment of a corporate representative.
The appointment of a corporate representative must be received by the
Company before the meeting or at the registration desk on the day of the
Meeting. Certificates of appointment of corporate representatives are
available at https://www.linkmarketservices.com.au/corporate/forms/holdingmanagement/App_Corp_Rep_140312.pdf or on request by calling +61 1300
554 474.
LODGING PROXY FORMS
Deadline
Proxy Forms must be received by 10:00am (AWST) on Tuesday, 14
November 2023.
How to lodge Proxy Forms
You can lodge your Proxy Form with the Company by:
Online: At https://investorcentre.linkgroup.com
Mail: to Orbital Corporation Limited C/- Link Market Services Limited, Locked
Bag A14, Sydney South NSW 1235, Australia.
Delivery: to Link Market Services Limited, Parramatta Square, Level 22,
Tower 6, 10 Darcy Street, Parramatta NSW 2150, Australia.
Facsimile: +61 2 9287 0309
Further details on how to lodge your Proxy Form can be found on the reverse
side of the Proxy Form.
ENQUIRIES
If you have any questions about this Notice or your Proxy Form please
contact the Company’s share registry, Link Market Services Limited, by
calling +61 1300 554 474.
By order of the Board of Directors
Thomas Spencer
Company Secretary
13 October 2023
4
Orbital Corporation Limited
EXPLANATORY NOTES
ITEM 1 CHAIRMAN’S ADDRESS AND THE CEO’S REPORT
The Chair will address the Meeting and the CEO will make a presentation on
the performance of the Company during the financial year ended 30 June
2023, as well as other strategic and operational activities of the Company.
The Chair will also allow time at the end of the Meeting to respond to
questions by Shareholders at or before the Meeting.
ITEM 2 DISCUSSION OF FINANCIAL STATEMENTS AND
REPORTS
In accordance with the Corporations Act, Shareholders will have a
reasonable opportunity to ask questions or make comments on the
Company’s Financial Report, Directors’ Report and Auditor’s Report for the
year ended 30 June 2023.
The Company’s auditor, PricewaterhouseCoopers will be present at the
Meeting and Shareholders will have an opportunity to ask the auditor
questions in relation to the conduct of the audit, the Auditor’s Report, the
Company’s accounting policies and the independence of the auditor.
The auditor will also respond to any written questions provided these are
submitted to the Company no later than five business days prior to the
Meeting.
There is no requirement for Shareholders to approve the Company’s
Financial Report, Directors’ Report and Auditor’s Report.
A copy of the Company’s 2023 Annual Report, which includes the Company’s
Financial Report, Directors’ Report and Auditor’s Report is available on the
Company’s website: https://orbitaluav.com/.
Voting prohibition statement
In accordance with the Corporations Act, the Company will disregard any
votes cast on Item 3:
•
by or on behalf of a member of Key Management Personnel (details of
whose remuneration are including in the Remuneration Report), or their
Closely Related Parties, regardless of the capacity in which the votes are
cast; or
•
by a person who is a member of the Key Management Personnel at the
date of the Meeting, or their Closely Related Parties, as a proxy.
However, votes will not be disregarded if they are cast as a proxy for a person
entitled to vote on Item 3:
•
in accordance with a direction as to how to vote on the proxy; or
•
by the Chair pursuant to an express authorisation to exercise the proxy
even though this Item 3 is connected directly or indirectly with the
remuneration of the Key Management Personnel.
ITEM 4 RE-ELECTION OF DIRECTOR
Mr Frederick (Kyle) Abbott was last re-elected to the Board on 13 November
2020.
In accordance with Listing Rule 14.4 and article 9.3 of the Constitution, Mr
Abbott will retire and being eligible, offer himself for re-election as this is the
third annual general meeting since he was last elected. His relevant skills
and experience and other ASX listed directorships are summarised below.
Mr Kyle Abbott
B.Com (Hons 1st), CA
ITEM 3 REMUNERATION REPORT
Background
The Remuneration Report for the financial year ended 30 June 2023 is
included in the Company’s 2023 Annual Report and sets out the Company’s
remuneration arrangements for Directors and executive staff.
The Chair will allow a reasonable opportunity for Shareholders to ask
questions about or make comments on the Remuneration Report at the
Meeting. Shareholders will then be asked to vote on the Remuneration
Report.
The vote is advisory only and does not bind the Company or its Directors.
The Company’s board (Board) will consider the outcome of the vote and
comments made by Shareholders on the Remuneration Report at the
meeting when reviewing the Company’s remuneration policies.
No spill resolution
If at least 25% of votes that are cast are voted against the adoption of the
Company’s Remuneration Report at two consecutive annual general
meetings, Shareholders must vote on whether the Board (other than any
managing director) should go up for re-election.
At the Company’s 2022 annual general meeting, less than 25% of the votes
cast on the resolution to adopt the 2022 Remuneration Report were voted
against the resolution. Accordingly no spill resolution will be held at this
Meeting.
Board recommendation
The Board abstains, in the interests of good corporate governance, from
making a recommendation in relation to the adoption of the Remuneration
Report.
The Chair intends to vote undirected proxies in favour of Item 3 in
accordance with the express authorisation on the Proxy Form.
Term
Initially appointed to the Board on 1 May 2018.
Independent
Yes, Mr Abbott is an independent non-executive
Director.
Skills and
experience
Mr Abbott is an experienced aerospace and defense
industry executive. Mr Abbott was Managing Director
of Western Australian Specialty Alloys (WASA) from
1996 to 2015. During this period WASA grew from a
Western Australian specialised alloy manufacturer to
become a major supplier to the global aerospace
industry, with key customers in the United States, the
United Kingdom and Japan. In 2000, Mr Abbott
managed the successful sale of WASA to United
States-based Precision Castparts Corporation (PCC),
an S&P 500 company. PCC was subsequently
acquired by Berkshire Hathaway in 2015.
Other ASX
listed
directorships
Nil
Special
Mr Abbott is a member of the Audit and Risk
responsibilities Committee
Interests in the 105,000 Shares
Company
25,000 Options
If Item 4 is passed, Mr Abbott will be re-elected as a Director.
If Item 4 is not passed, Mr Abbott will cease to be a Director at the conclusion
of the Meeting.
5
Orbital Corporation Limited
EXPLANATORY NOTES
Board recommendation
The Board (other than Mr Abbott who has an interest in Item 4) believe
that the re-election of Mr Abbott is in the best interests of the Company,
as his skills and experience align with the Company’s strategic direction,
and unanimously recommend that Shareholders vote in favour of the reelection of Mr Abbott.
The Chair intends to vote undirected proxies in favour of Item 4.
ITEMS 5 AND 6 RATIFICATION OF TRANCHE 1 PLACEMENT
SHARES ISSUED UNDER LISTING RULES 7.1 & 7.1A
General
On 26 September 2023, the Company announced that it had received firm
commitments for a placement of new Shares to raise $4 million (before costs)
at $0.14 per Share to be issued by the Company (Placement). The
Placement comprises the following two tranches.
a) the first tranche of the Placement (Tranche 1 Placement)
comprises 21,428,572 Shares (Tranche 1 Placement Shares),
which were issued on 27 September 2023 utilising the Company's
existing placement capacity pursuant to Listing Rule 7.1
(17,318,531 of the Tranche 1 Placement Shares) and Listing Rule
7.1A (4,110,041 of the Tranche 1 Placement Shares); and
b) the second tranche of the Placement (Tranche 2 Placement)
comprises a further 7,142,857 Shares to be issued, subject to
Shareholder approval (which is being sought pursuant to Item 7),
to the largest Shareholder, UIL Limited (Tranche 2 Placement
Shares).
Pursuant to the Tranche 1 Placement, 20,000,000 of the Tranche 1
Placement Shares were issued to Boneyard Investments Pty Ltd (being a
nominee of Mr Gordon Martin) and the remaining 1,428,572 Tranche 1
Placement Shares in aggregate were issued to Maglo Investments Pty Ltd
(being a nominee of Mr Grant Lukey) and TJM Australia Trust Pty Ltd (being
a nominee of Mr Timn Martin). Mr Gordon Martin is the majority shareholder
and current Executive Director of Coogee Chemicals Pty Ltd (Coogee) and
has a long history of championing Western Australian operated businesses.
Mr Tim Martin is the Executive Chairman of Coogee and Dr Grant Lukey is
the Chief Executive Officer & Managing Director of Coogee.
The Placement is intended to support the Company's existing engine
development programs, with approximately $3 million allocated to contribute
towards funding the development of a larger engine platform, a high-volume
low-cost engine as well as further hybrid and power management system
development and approximately $1 million being proposed to be allocated
towards general working capital. The Board reserves the right to reallocate
funds for alternative purposes, as may be deemed necessary by the Board.
The lead manager for the Placement was Poynton Stavrianou Pty Ltd (ABN
68 609 851 587).
Refer to the Company's ASX announcements on, and after, 26 September
2023 for further details of the Placement.
Board recommendation
The Board unanimously recommends Shareholders vote in favour of
ratifying and approving the issue of the Tranche 1 Placement Shares
under Listing Rules 7.1 and 7.1A.
The Chair intends to vote undirected proxies in favour of Items 5 and 6.
Voting exclusion statement
The Company will disregard any votes cast in favour of Item 5 or Item 6 by
or on behalf of a person who participated in the issue of Shares pursuant to
the Tranche 1 Placement (being Boneyard Investments Pty Ltd, Maglo
Investments Pty Ltd and TJM Australia Trust Pty Ltd) or an associate of any
of those persons.
However, this does not apply to a vote cast in favour of Item 5 or Item 6 by:
•
a person as proxy or attorney for a person who is entitled to vote on the
Item, in accordance with directions given to the proxy or attorney to vote
on the Item in that way; or
•
the Chair as proxy or attorney for a person who is entitled to vote on the
Item, in accordance with a direction given to the Chair to vote on the Item
as the Chair decides; or
•
a holder acting solely in a nominee, trustee, custodial or other fiduciary
capacity on behalf of a beneficiary provided the following conditions are
met:
o the beneficiary provides written confirmation to the holder
that the beneficiary is not excluded from voting, and is not an
associate of a person excluded from voting, on the Item; and
o the holder votes on the Item in accordance with directions
given by the beneficiary to the holder to vote in that way.
Listing Rule 7.1
Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1
limits the amount of Equity Securities that a listed company can issue without
the approval of its shareholders over any 12 month period to 15% of the fully
paid ordinary securities it had on issue at the start of that period (15%
Placement Capacity).
In addition to its 15% Placement Capacity, the Company obtained
Shareholder approval pursuant to Listing Rule 7.1A at its 2022 annual
general meeting to issue Equity Securities up to 10% of its issued share
capital through placements over a 12-month period after the Company’s
2022 annual general meeting, without needing prior Shareholder approval
(10% Placement Facility).
The issue of the Tranche 1 Placement Shares does not fall within any of the
exceptions to Listing Rule 7.1, and, as it has not yet been approved by
Shareholders, it effectively uses up the Company's 15% Placement Capacity
in Listing Rule 7.1 and part of the Company's 10% Placement Facility,
reducing the Company's capacity to issue further Equity Securities without
Shareholder approval under Listing Rule 7.1 and 7.1A.
Listing Rule 7.4 allows the shareholders of a listed company to approve an
issue of Equity Securities after it has been made or agreed to be made. If
they do, the issue is taken to have been approved under Listing Rule 7.1 or
Listing Rule 7.1A (as applicable) and consequently does not reduce the
company’s capacity to issue further Equity Securities without shareholder
approval under that applicable rule.
The Company wishes to retain as much flexibility as possible to issue
additional Equity Securities into the future without having to obtain
Shareholder approval for such issues under Chapter 7 of the Listing Rules.
To this end, Items 5 and 6 seek Shareholder ratification and approval for the
Tranche 1 Placement Shares under and for the purposes of Listing Rule 7.4
(and for all other purposes).
If Item 5 is passed, the issue of the 17,318,531 Tranche 1 Placement Shares
the subject of that Item will be excluded in calculating the Company’s 15%
Placement Capacity in Listing Rule 7.1, effectively increasing the number of
Equity Securities it can issue without Shareholder approval over the 12 month
period following the issue of those Tranche 1 Placement Shares.
If Item 5 is not passed, the 17,318,531 Tranche 1 Placement Shares the
subject of that Item will be included in calculating the Company’s 15%
Placement Capacity in Listing Rule 7.1, effectively decreasing the number of
Equity Securities it can issue without Shareholder approval over the 12 month
period following the issue of those Tranche 1 Placement Shares.
6
Orbital Corporation Limited
EXPLANATORY NOTES
If Item 6 is passed, the issue of the 4,110,041 Tranche 1 Placement Shares
the subject of that Item will be excluded in calculating the Company’s 10%
Placement Facility in Listing Rule 7.1A, effectively increasing (subject, in the
case of that 10% Placement Facility, to Item 8 also being passed) the number
of Equity Securities it can issue without Shareholder approval over the 12
month period following the issue of those Tranche 1 Placement Shares.
If Item 6 is not passed, the 4,110,041 Tranche 1 Placement Shares the
subject of that Item will be included in calculating the Company’s 10%
Placement Facility in Listing Rule 7.1A, effectively decreasing the number of
Equity Securities it can issue without Shareholder approval over the 12 month
period following the issue of those Tranche 1 Placement Shares.
Specific Information required by Listing Rule 7.5
The following information in relation to Items 5 and 6 is provided to
Shareholders for the purposes of Listing Rule 7.5:
a) 21,428,572 Tranche 1 Placement Shares were issued to
sophisticated investors on 27 September 2023, as detailed in the
general information to Items 5 and 6. None of the recipients were
related parties of the Company or associates of related parties of
the Company.
b) The Tranche 1 Placement Shares comprised:
i)
the issue of 17,318,531 Tranche 1 Placement Shares
pursuant to the Company's 15% Placement Capacity
under Listing Rule 7.1, ratification of which is sought
pursuant to Item 5; and
ii)
the issue of 4,110,041 Tranche 1 Placement Shares
pursuant to the Company's 10% Placement Facility under
Listing Rule 7.1A, ratification of which is sought pursuant
to Item 6.
c) The Tranche 1 Placement Shares are fully paid ordinary shares in
the capital of the Company and rank equally in all respects with
the Company’s existing Shares on issue.
d) The Tranche 1 Placement Shares were issued in consideration for
an issue price of $0.14 per Share, raising a total of approximately
$3 million (before costs).
e) The Tranche 1 Placement Shares were issued on 27 September
2023.
f) Funds raised from the issue of the Tranche 1 Placement Shares
will be used for the purposes detailed in the general information to
Items 5 and 6.
g) The Tranche 1 Placement Shares were issued pursuant to
subscription letters pursuant to which subscribers under the
Tranche 1 Placement applied for Tranche 1 Placement Shares at
an issue price of $0.14 per Share.
h) A voting exclusion statement is included in this Notice for Items 5
and 6.
ITEM 7 ISSUE OF TRANCHE 2 PLACEMENT SHARES TO UIL
LIMITED
General
Refer to the general information in Items 5 and 6 for a summary of the
Tranche 2 Placement.
UIL Limited has committed to invest approximately $1,000,000 under the
Tranche 2 Placement, comprising the subscription for all the Tranche 2
Placement Shares (being 7,142,857 Shares), at an issue price of $0.14 per
Tranche 2 Placement Share. The issue of the Tranche 2 Placement Shares
to UIL Limited is subject to Shareholder approval, which is being sought
pursuant to Item 8 (pursuant to and in accordance with Listing Rule 10.11
(and for all other purposes)). If the Tranche 2 Placement Shares are issued,
UIL Limited would (subject to any further changes in the Company's capital
structure or UIL Limited's interests, and assuming no options in the Company
(Options) are exercised) hold a relevant interest in approximately 31% of the
Shares upon completion of the Tranche 2 Placement.
UIL Limited is a party falling within Listing Rule 10.11, because UIL Limited
was, at any time in the last six months, a substantial holder of 30% or more
in the Company.
The issue of the Tranche 2 Placement Shares does not fall within any of the
exceptions to Listing Rule 10.11 (and it exceeds the 15% Placement
Capacity).
If Item 7 is passed, the Company will be able to proceed with the issue of the
Tranche 2 Placement Shares, and (pursuant to Listing Rule 7.2, exception
14) the Company may issue the Tranche 2 Placement Shares without using
up any of the Company's 15% Placement Capacity under Listing Rule 7.1.
If Item 7 is not passed, the issue of the Tranche 2 Placement Shares to UIL
Limited will not proceed, meaning that the Company will not be able to raise
funds pursuant to that issue of the Tranche 2 Placement Shares and may
seek to raise them from alternate investors.
Board recommendation
The Board unanimously recommends Shareholders vote in favour of
approving the issue of the Tranche 2 Placement Shares to UIL Limited
under the Tranche 2 Placement.
The Chair intends to vote undirected proxies in favour of Item 7.
Voting exclusion statement
The Company will disregard any votes cast in favour of Item 7 by or on behalf
of UIL Limited and any other person who will obtain a material benefit as a
result of the proposed issue of the securities (except a benefit solely by
reason of being a holder of ordinary securities in the Company) or an
associate of UIL Limited or of any of the other abovementioned persons.
However, this does not apply to a vote cast in favour of Item 7 by:
• a person as proxy or attorney for a person who is entitled to vote
on this Item, in accordance with directions given to the proxy or
attorney to vote on this Item in that way; or
• the Chair as proxy or attorney for a person who is entitled to vote
on the Item, in accordance with a direction given to the Chair to
vote on the Item as the Chair decides; or
• a holder acting solely in a nominee, trustee, custodial or other
fiduciary capacity on behalf of a beneficiary provided the following
conditions are met:
o the beneficiary provides written confirmation to the holder
that the beneficiary is not excluded from voting, and is not an
associate of a person excluded from voting, on this Item; and
o the holder votes on this Item in accordance with directions
given by the beneficiary to the holder to vote in that way.
7
Orbital Corporation Limited
EXPLANATORY NOTES
Listing Rule 10.11
Listing Rule 10.11 provides that unless one of the exceptions in Listing Rule
10.12 applies, a listed company must not issue or agree to issue Equity
Securities to:
a) a related party;
b) a person who is, or was at any time in the six months before the
issue or agreement, a substantial (30%+) holder in the company;
c) a person who is, or was at any time in the six months before the
issue or agreement, a substantial (10%+) holder in the company
and who has nominated a director to the board of the company
pursuant to a relevant agreement which gives them a right or
expectation to do so;
d) an associate of a person referred to in (a) to (c); or
e) a person whose relationship with the company or a person referred
to in (a) to (d) is such that, in ASX’s opinion, the issue or
agreement should be approved by its shareholders,
unless it obtains shareholder approval.
The issue of the Tranche 2 Placement Shares to UIL
Share your feedback
Discover